Mineralys Therapeutics
MLYS
22.09
+0.14
+0.64%
Mineralys Therapeutics
US · MLYS
#2760 by market cap
Listed 2023
22.09
+0.14
+0.64%
Live - 5344 symbols - heartbeat 93s ago
· 2026-10-08 09:19
Pre-market
22.49
+1.81%
After-hours
22.38
+1.31%
Overnight
22.50
+1.86%
- Market cap
- 1.95B
- P/E (TTM)i
- -5.26
- P/Bi
- 3.54
- EPSi
- -2.29
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on MLYS?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 6 analysts
Buy
Avg price target
51.00 +130.9%
Price target rangecurrent 22.09
Low40.00
Avg51.00
High56.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-12 | Wells Fargo | -- | BUY | 55.00 |
| 2026-08-12 | LifeSci Capital | -- | BUY | 54.00 |
| 2026-08-12 | BofA Securities | -- | BUY | 49.00 |
| 2026-08-12 | Goldman Sachs | -- | BUY | 40.00 |
| 2026-08-12 | Guggenheim | -- | BUY | 52.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 56.00 |
| 2026-06-03 | Goldman Sachs | -- | BUY | 42.00 |
| 2026-06-01 | LifeSci Capital | -- | BUY | 54.00 |
| 2026-06-01 | H.C. Wainwright | -- | BUY | 56.00 |
| 2026-05-18 | Goldman Sachs | -- | BUY | 42.00 |
| 2026-05-18 | Guggenheim | -- | BUY | 48.00 |
| 2026-05-09 | LifeSci Capital | -- | BUY | 54.00 |
| 2026-05-07 | LifeSci Capital | -- | BUY | 54.00 |
| 2026-05-07 | BofA Securities | -- | BUY | -- |
| 2026-05-07 | Stifel | -- | BUY | 52.00 |
| 2026-05-07 | Goldman Sachs | -- | BUY | 42.00 |
| 2026-05-07 | H.C. Wainwright | -- | BUY | 56.00 |
| 2026-05-06 | TD Cowen | -- | BUY | -- |
| 2026-04-27 | TD Cowen | -- | BUY | -- |
| 2026-03-16 | H.C. Wainwright | -- | BUY | 56.00 |
| 2026-03-13 | Wells Fargo | -- | BUY | 55.00 |
| 2026-03-13 | BofA Securities | -- | BUY | 51.00 |
| 2026-03-13 | Stifel | -- | BUY | 52.00 |
| 2026-03-12 | BofA Securities | -- | BUY | 51.00 |
| 2026-03-12 | Guggenheim | -- | BUY | 48.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-11 | After close | ±7.52% | -1.02% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±13.31% | -2.56% (in line) |
| 2025/Q4 | 2026-03-12 | After close | ±12.23% | -2.96% (in line) |
| 2025/Q3 | 2025-11-10 | After close | ±10.32% | +5.87% (in line) |
| 2025/Q2 | 2025-08-12 | After close | ±17.39% | +0.37% (in line) |
| 2025/Q1 | 2025-05-12 | After close | ±12.27% | +1.20% (in line) |
| 2024/Q4 | 2025-02-12 | -- | -- | +10.04% |
| 2024/Q3 | 2024-11-11 | After close | -- | -10.32% |
| 2024/Q2 | 2024-08-13 | After close | ±37.60% | -22.82% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±31.98% | -2.59% (in line) |
| 2023/Q4 | 2024-03-21 | -- | -- | -2.24% |
| 2023/Q3 | 2023-11-07 | After close | -- | -6.74% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 09:19:49 · For reference only, not investment advice and not tailored to your situation.